A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence

Subjects will be given up to 2 treatments of NASHA/Dx or sham and followed for 6 months from last treatment (ie, one retreatment is permitted at 1 month after the first injection) in the blinded phase of the study. At Month 6, the open phase of the study will begin and subjects on sham will be offered open-label treatment with NASHA/Dx.

Subjects who receive NASHA/Dx at the start of the blinded phase will be followed for up to 36 months from last treatment in the blinded phase. Subjects who receive sham at the start of the blinded phase and then receive open-label NASHA/Dx at Month 6 (start of the open phase) will be followed for another 24 months (equivalent to approximately 30 months from randomization) from last treatment in the open phase of the study.

Inclusion criteria

• 18-75 years of age, male or female.
• Screening fecal incontinence severity score (CCFIS).
• Fecal incontinence episodes over a 14-day period.
• Failed conservative treatment for fecal incontinence.

Exclusion criteria

• Complete external sphincter disruption.
• Significant anorectal disease.
• Anorectal surgery within the last 12 months prior to the study.
• Active Inflammatory Bowel Disease (IBD).
• Immunodeficiency or receiving immunosuppressive therapy.
• Malignancies in remission for less than 2 years prior to the study.
• Bleeding disorders or receiving anticoagulant therapy.
• Chemotherapy within the last 12 months prior to the study.
• Prior Pelvic radiotherapy.
• Women who are pregnant or breast-feeding, or women of childbearing potential not practicing adequate contraception or planning to stop such contraception within the first year of the study.
• Women within one year post partum.
• Participation in any other clinical study within 3 month prior to the study.
• Hypersensitivity to hyaluronic acid containing products.
• Other severe conditions or in other ways unsuitable to participate according to investigator judgement.